Newly updated HIV/AIDS treatment guidelines, issued by the International AIDS Society-USA and published in this week’s edition of the Journal of the American Medical Association, support important changes for the management of treatment-experienced patients. They recommend for the first time that the goal of therapy in heavily treatment-experienced patients should be to achieve undetectable levels of HIV (less than 50 copies/mL), and highlight the results from several pivotal studies with newer anti-HIV treatments, such as darunavir and tipranavir, in which concomitant use of FUZEON was associated with a significantly greater likelihood of achieving this result. FUZEON, the first and only fusion inhibitor available for the treatment of HIV, was co-developed by Roche and Trimeris (Nasdaq: TRMS). The revised IAS-USA guidelines were released in a news conference at the XVI International AIDS Conference, being held this week in Toronto.
